Hanmi Leads Domestic Outpatient Prescription Performance for 4 Consecutive Years... 742 Billion KRW

Hanmi Pharm Headquarters Exterior (Photo by Hanmi Pharm)

[Asia Economy Reporter Chunhee Lee] Hanmi Pharmaceutical has achieved the number one position in domestic outpatient prescription performance for four consecutive years. The number of blockbuster drugs with annual prescription sales exceeding 10 billion KRW has also increased to 16.

Hanmi Pharmaceutical announced on the 19th that it achieved outpatient prescription sales of 742 billion KRW (based on UBIST) last year, maintaining its number one position in the domestic outpatient prescription market for four consecutive years since 2018. This represents a 3.8% growth compared to the previous year's prescription amount of 697 billion KRW. UBIST is data that calculates the quantity and sales amount of prescription drugs prescribed by doctors to patients visiting hospitals based on medical treatment.

Hanmi Pharmaceutical has achieved continuous growth despite the sharp decline in hospital visits due to the recent ongoing COVID-19 pandemic. The company explained, "this is the result of synergy between high-quality drugs launched based on creative formulation technology and Hanmi's unique evidence-based marketing."

The number of blockbuster drugs with sales exceeding 10 billion KRW has increased to 16. In particular, the explosive growth of the combination drug for dyslipidemia treatment, 'Rosuzet,' stood out. Rosuzet's sales in 2021 reached 123.2 billion KRW, making it the highest prescription sales among domestically developed drugs by Korean pharmaceutical companies. It also grew by 17.4% compared to 104.9 billion KRW the previous year. In addition, ▲the antihypertensive drug 'Amozantan' (83.6 billion KRW) ▲the gastroesophageal reflux disease drug 'Esomazol' (53.8 billion KRW) ▲the benign prostatic hyperplasia drug 'Hanmi Tams' (31.7 billion KRW) ▲the antihypertensive drug 'Amozantan Plus' (28.2 billion KRW) ▲the antihypertensive drug 'Amodipine' (24.3 billion KRW) continued the blockbuster record.

Also, ▲the overactive bladder treatment 'Mirabec' (11.5 billion KRW), ▲the blood circulation enhancer 'Hanmi Omega' (10.1 billion KRW), ▲the hypertriglyceridemia treatment 'Fenocid' (10 billion KRW) newly joined Hanmi's blockbuster product lineup. All of these are drugs developed independently by Hanmi Pharmaceutical.

In addition, including non-reimbursed drugs such as ▲the erectile dysfunction treatment 'Palpal' (44.2 billion KRW) and ▲the erectile dysfunction and benign prostatic hyperplasia treatment 'Gugu' (19.4 billion KRW), Hanmi Pharmaceutical's blockbuster drugs total 18.

Hanmi Pharmaceutical continues to hold the number one position not only in sales but also in production. According to the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Hanmi Pharmaceutical's drug production performance in 2020 was 1.0118 trillion KRW, the highest among domestic pharmaceutical companies. This marks the third consecutive year of holding the top position since 2018.

Woosung Su, CEO of Hanmi Pharmaceutical, said, “In 2021, 93.5% of Hanmi Pharmaceutical's prescription sales came from independently developed products using our own technology, demonstrating Hanmi's commitment to protecting pharmaceutical sovereignty and evolving as a ‘sustainable innovation company.’ We will continue to develop creative and high-quality drugs to contribute not only to the convenience of medical professionals and patients but also to the reduction of national health insurance finances.”